With the pricing situation ‘untenable’ in Europe, Bluebird will wind down its operations in the ‘broken’ marketnews2021-08-09T15:33:01+00:00August 9th, 2021|Fierce Pharma|
BioNTech, eyeing $18B-plus in COVID-19 vaccine sales this year, poised to join the ranks of the world’s top drugmakersnews2021-08-09T15:17:12+00:00August 9th, 2021|Fierce Pharma|
In $2.6B cancer deal, Seagen bets China’s first homemade ADC can challenge Roche, AZ-Daiichinews2021-08-09T14:24:10+00:00August 9th, 2021|Fierce Pharma|
Roche snags coveted Polivy win in newly diagnosed lymphoma. But is it enough to change 2 decades of established treatment practices?news2021-08-09T12:14:59+00:00August 9th, 2021|Fierce Pharma|
AstraZeneca, Daiichi Sankyo build Enhertu’s blockbuster case with breast cancer win against Roche’s Kadcylanews2021-08-09T09:53:15+00:00August 9th, 2021|Fierce Pharma|
Sanofi notches another Pompe win with FDA blessing for enzyme replacement therapy Nexviazymenews2021-08-06T18:44:08+00:00August 6th, 2021|Fierce Pharma|
From vaccine halo to liability? Reputation tracker says COVID-19 shot makers now dinged for safety, supply issuesnews2021-08-06T18:24:09+00:00August 6th, 2021|Fierce Pharma|
Gilead cracks down on fake versions of popular HIV drugs Biktarvy, Descovy being sold at US pharmaciesnews2021-08-06T15:06:03+00:00August 6th, 2021|Fierce Pharma|
Sanofi and Regeneron solidify Dupixent TV ad lead, topping July pharma spenders again, trailed by AbbVie and Novo Nordisknews2021-08-06T14:34:16+00:00August 6th, 2021|Fierce Pharma|
Sanofi and Regeneron solidify Dupixent TV ad lead in July, trailed by AbbVie and Novo Nordisknews2021-08-06T14:34:16+00:00August 6th, 2021|Fierce Pharma|
